New drug combo before fertility-sparing surgery for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have cervical cancer that has not spread beyond the cervix (nodal or distant spread).
- You want to keep your ability to have children in the future.
- Your overall health is good (able to do daily activities without major issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This study looks at whether giving chemotherapy before surgery (neoadjuvant chemotherapy) can shrink certain cervical cancers enough to allow fertility-sparing surgery. It may help some people avoid removing the uterus, while still treating the cancer effectively.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
Hear when a new Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.